<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-366-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ASACOL 400MG F.C TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MESALAZINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="WULFING PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            WULFING PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            TILLOTTS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A07EC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Asacol contains the active substance mesalazine. This is an anti-inflammatory medicine used to treat ulcerative colitis and Crohn&rsquo;s ileo-colitis.</p><p>Asacol is used:</p><p>&middot;&nbsp;&nbsp;&nbsp; to treat and prevent further episodes of ulcerative colitis</p><p>&middot;&nbsp;&nbsp;&nbsp; to prevent further episodes of Crohn&rsquo;s ileo-colitis once the disease has been brought under control.</p><p>&nbsp;</p><p>Ulcerative colitis is a disease of the large bowel (colon) or back passage (rectum), in which the lining of the bowel becomes inflamed (red and swollen).</p><p>Crohn&rsquo;s ileo-colitis is a disease that affects the small bowel (terminal ileum) and the large bowel (colon) in which the lining of the bowel becomes inflamed. This can lead to ulcers, abscesses and narrowing (strictures) in the bowel.</p><p>Asacol acts locally at the site of inflammation (colon, rectum and terminal ileum) to reduce this inflammation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Asacol</strong></p><p>Do not use Asacol in the following cases:</p><p>severe liver and kidney dysfunction; allergy to salicylates; hypersensitivity to mesalazine or any of the other ingredients; children under 2 years.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>In particular, tell your doctor or pharmacist if you have kidney dysfunction.</p><p>&nbsp;</p><p>If you notice any unexplained bleeding, bruising, pinpoint bleeding in the skin, anaemia, persistent fever or sore throat, stop the treatment immediately and consult your doctor immediately, as your blood count might have changed. Your doctor will know what to do in such cases.</p><p>&nbsp;</p><p>If acute intolerance reactions should occur, such as cramps, abdominal pain, fever, severe headache or rash, stop the treatment immediately and contact your doctor.</p><p>&nbsp;</p><p>Talk to your doctor before using Asacol if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after using mesalazine.</p><p>Serious skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis have been reported in association with mesalazine treatment. Stop using mesalazine and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.</p><p>&nbsp;</p><p>Caution is advised when Asacol is administered to patients with liver or kidney dysfunction and in patients with a history of hypersensitivity reactions affecting the heart (myocarditis and pericarditis), irrespective of their cause.</p><p>&nbsp;</p><p>Before and during treatment with Asacol, your doctor will consider whether you need regular examinations to check that your liver, kidneys, lungs and blood are normal. It is recommended that you keep all appointments for tests arranged by your doctor.</p><p>&nbsp;</p><p>Treatment should be started with caution if you have a stomach or intestinal ulcer or lung disease, especially asthma.</p><p>&nbsp;</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should seek medical advice before starting treatment.</p><p>&nbsp;</p><p>There are a limited number of reports of intact tablets appearing in the stool. These seemingly intact tablets may, in some cases, represent largely empty shells from the coated tablets.</p><p>If you keep noticing tablets in your stools, you should consult your doctor.</p><p>&nbsp;</p><p>In elderly patients, Asacol is only recommended for use if kidney and liver function is normal, and caution should generally be exercised.</p><p>&nbsp;</p><p>Kidney stones may develop with use of mesalazine. Symptoms may include pain in sides of abdomen and blood in urine. Take care to drink sufficient amount of liquid during treatment with mesalazine.</p><p>&nbsp;</p><p><strong>Children</strong></p><p>Asacol is only recommended for use in children 6 years and older.</p><p>&nbsp;</p><p><strong>Other medicines and Asacol</strong></p><p>Tell your doctor or pharmacist if you are suffering from other illnesses, have any allergies or are taking or externally using other medicines (including those purchased without a prescription).</p><p>&nbsp;</p><p>There are known drug interactions with warfarin and phenprocoumon (anticoagulants), azathioprine (an immunosuppressant), as well as mercaptopurine and thioguanine (cytostatics).</p><p>&nbsp;</p><p>Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach in the toilet water. It concerns a chemical reaction between mesalazine and bleach and is harmless.</p><p>&nbsp;</p><p><strong>Pregnancy and breastfeeding</strong></p><p>Asacol is excreted in human milk. During pregnancy and breast-feeding, Asacol should be used only after consultation with your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Asacol has no or negligible influence on the ability to drive and use machines. However, if you are affected in anyway, do not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Asacol should be taken before meals. This medication must be swallowed whole preferably with some liquid. Do not chew, crush or break the tablets before swallowing them</p><p>Whilst taking this medication ensure you drink adequate fluids to remain well hydrated, especially after severe or prolonged episodes of vomiting and/or diarrhoea, high fever or heavy sweating. This is to avoid problems with your kidney.</p><p>&nbsp;</p><p><strong>The recommended dose is:</strong></p><p><strong>Adults (including the elderly)</strong></p><p>To treat ulcerative colitis, your daily dose is 6 to 12 tablets. 6 tablets may be taken once daily or in divided doses (as advised by your doctor). Above 6 tablets a day should be taken in divided doses.</p><p>&nbsp;</p><p>To prevent Crohn&rsquo;s ileo-colitis or ulcerative colitis your daily dose is 3 to 6 tablets once daily or in divided doses. Follow your doctor&rsquo;s instructions. Do not take more than 12 tablets a day and do not take more than 6 tablets at the same time.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>Asacol is only recommended for use in children 6 years and older. The daily dose depends on the child&rsquo;s weight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To treat acute phases of ulcerative colitis:</p><p>&nbsp;20-30 kg weight: two to three tablets per day.</p><p>&nbsp;30-40 kg weight: two to four tablets per day in divided doses. 40 kg weight: three to five tablets per day in divided doses. The total dose should not exceed 4 g/day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prevent ulcerative colitis or Crohn&rsquo;s ileo-colitis:</p><p>&nbsp;20-30 kg weight: one tablet per day.</p><p>&nbsp;30-40 kg weight: one to 2 tablets per day</p><p>&nbsp;40 kg weight: one to three tablets per day in divided doses. The total dose should not exceed 2 g/day.</p><p>It is generally recommended that half the adult dose may be given to children up to 40 kg weight; and the normal adult dose to those above 40 kg.</p><p>Do not change the prescribed dose by yourself. If you think that the effect of the medicine is too weak or too strong, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>If you take more Asacol than you should</p><p>You should not take a higher dose than your doctor has prescribed for you. Contact your nearest hospital casualty department or a doctor for advice if you or anyone else has swallowed too many tablets or if you think a child has swallowed any. Take this leaflet, and any tablets that you still have to show the doctor.</p><p>&nbsp;</p><p>If you forget to take Asacol</p><p>If you forget to take a tablet, take one as soon as you remember unless it is nearly time to take the next one. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop taking Asacol</p><p>Do not stop taking Asacol without talking to your doctor first even if you feel better. If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Taking Asacol with food and drink</strong></p><p>Where possible, the administration of the tablets should take place before a meal with a glass of liquid.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Organ specific side effects affecting the heart, lungs, liver, kidneys, pancreas, skin and subcutaneous tissue have been reported.</p><p><strong><u>Stop taking this medicine at once and seek urgent medical advice immediately if you notice any of the following symptoms:</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes, widespread rash, fever and enlarged lymph nodes. These serious skin rashes can be preceded by fever and flu-like symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexplained bruising (without injury), bleeding under your skin, purple spots or patches under your skin, anaemia (feeling tired, weak and looking pale, especially on lips, nails and inside of eyelids), fever (high temperature), sore throat or unusual bleeding (e.g., nose bleeds).</p><p>&nbsp;</p><p>The following side effects have been reported at the approximate frequencies shown:</p><p>&nbsp;</p><p><strong>Common: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&nbsp;</p><p><strong>Uncommon </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high number of white blood cells called eosinophil granulocytes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of tingling, pricking and numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives, itching skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&nbsp;</p><p><strong>Rare</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the heart with signs like chest pains or palpitations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, stomach pain, wind (flatulence), feeling of unease and discomfort in the stomach with an urge to vomit and vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity of your skin to sun and ultraviolet light (photosensitivity).</p><p><strong>&nbsp;</strong></p><p><strong>Very rare </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe reduction in blood cells which can cause weakness, bruising or make infections more likely, low blood cell counts; reduction in blood platelets which increases the risk of bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions such as rash or skin eruption</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever that occurs while taking the medicine and which disappears when the medicine is stopped (drug fever)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immune system disease that can involve organs and joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulcerative colitis involving the entire large intestine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal or damaged nerves giving a sensation of numbness or tingling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung disease (scarring of lung tissue, allergic reaction) resulting in difficulty in breathing, cough, wheezing and collection of fluid in the lungs, pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed pancreas (associated with pain in upper abdomen and back and feeling sick)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver function tests, hepatitis (inflammation of the liver giving rise to flu-like symptoms and jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle or joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems (such as inflammation and scarring of the kidney), kidney failure, which may be reversible if treatment is stopped early</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible decrease in sperm production.</p><p><strong>&nbsp;</strong></p><p><strong>Not known </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorder of the immune system (lupus-like syndrome) which can cause inflammation of the heart sac or membranes around the lungs and heart, rash and /or joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the membranes of the pleural cavity surrounding the lungs (pleurisy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intolerance to mesalazine sometimes with worsening symptoms of underlying disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; laboratory test results out of normal range.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney stones and associated kidney pain (see also section 2).</p><p>&nbsp;</p><p>Evaluation of the side effects is based on the following frequencies:</p><p>Common: may affect up to 1 in 10 people</p><p>Uncommon: may affect up to 1 in 100 people</p><p>Rare: may affect up to 1 in 1,000 people</p><p>Very rare: may affect up to 1 in 10,000 people</p><p>Not known: frequency cannot be estimated from the available data</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Asacol gastro-resistant tablets should be stored in their original pack at a temperature not exceeding 25 &deg;C and protected from moisture and direct sunlight.</p><p>This medicine must be used only until the date printed as &ldquo;EXP&rdquo; on the pack.</p><p>Keep out of the sight and reach of children.</p><p>You can obtain further information from your doctor or pharmacist, who will have comprehensive prescribing information at their disposal.</p><p>Do not use this medicine after the expiry date, which is stated on the outer packaging.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away any medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1 Asacol 400 mg gastro-resistant tablet contains 400 mg mesalazine.</p><p>&nbsp;</p><p>The other ingredients are: lactose monohydrate, povidone E1201, sodium starch glycolate, talc E 553b, magnesium stearate, triethylcitrate, talc E553b, yellow and red iron oxides E172, methacrylic acid&ndash;methylmethacrylate copolymer 1:2, macrogol 6000.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                In pharmacies on presentation of a doctor’s prescription.
Asacol 400 mg Gastro-resistant Tablets is offered in packs of 50. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The marketing authorisation holder is:</strong></p><p>Tillotts Pharma AG, Baslerstrasse 15</p><p>4310 Rheinfelden,</p><p>Switzerland</p><p>&nbsp;</p><p>The manufacturer is:</p><p>Haupt Pharma W&uuml;lfing GmbH, D &ndash; 31028 Gronau, Germany</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states: </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority</em></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Council of Arab Health Ministers</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong><em>This is a Medicament</em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament. </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>The doctor and the pharmacist are the experts in medicines, their benefits and risks. </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Do not by yourself interrupt the period of treatment prescribed for you. </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Do not repeat the same prescription without consulting your doctor.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Keep all medicaments out of reach of children.</em></p></td></tr></tbody></table><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This patient information leaflet was last revised in November 2022.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أساكول على المادة الفعالة ميسالازين. هذا دواء مضاد للالتهابات يستخدم لعلاج التهاب القولون التقرحي والتهاب كرونز اللفائفي والقولون.</p><p dir="RTL">يُستخدم أساكول:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; لعلاج نوبات التهاب القولون التقرحي ومنع حدوثها مجدداً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; لمنع حدوث المزيد من نوبات التهاب كرونز اللفائفي والقولون بعد السيطرة على المرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التهاب القولون التقرحي هو مرض يصيب الأمعاء الغليظة (القولون) أو المستقيم وتلتهب فيه بطانة الأمعاء (تصبح حمراء ومتورمة).</p><p dir="RTL">التهاب كرونز اللفائفي والقولون هو مرض يصيب الأمعاء الدقيقة (اللفائفي) والأمعاء الغليظة (القولون) وتلتهب فيه بطانة الأمعاء. ويمكن أن يؤدي هذا إلى حدوث تقرحات وخراجات وتضيق في الأمعاء.</p><p dir="RTL">يعمل أساكول في موضع الالتهاب (القولون والمستقيم واللفائفي) لتخفيف هذا الالتهاب.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">موانع استخدام أساكول</p><p dir="RTL">لا تستخدم أساكول في الحالات التالية:</p><p dir="RTL">الضعف الشديد في وظائف الكبد والكلى؛ الحساسية للساليسيلات؛ فرط الحساسية للميسالازين أو أي من المكونات الأخرى؛ الأطفال دون عمر السنتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استخدام أساكول</strong></p><p dir="RTL">على وجه الخصوص، أخبر طبيبك أو الصيدلي إذا كنت تعاني من ضعف في وظائف الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أي إصابة بنزيف دون سبب أو كدمات أو نمشات دموية أو فقر الدم أو ارتفاع مستمر في حرارة الجسم أو التهاب في الحلق، فأوقف العلاج واستشر طبيبك على الفور، فقد يكون هناك تغير في تعداد كريات الدم لديك. وسيعرف طبيبك ما عليه فعله هذه الحالات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة حدوث ردود فعل تحسسية شديدة، مثل التشنجات أو ألم البطن أو ارتفاع حرارة الجسم أو الصداع الشديد أو الطفح الجلدي، فأوقف العلاج فوراً واتصل بطبيبك.</p><p dir="RTL">تحدث إلى طبيبك قبل استخدام أساكول إذا كنت قد عانيت في أي وقت مضى من طفح جلدي شديد أو تقشير جلدي و / أو تقرحات و / أو تقرحات في الفم بعد استخدام الميسالازين.</p><p dir="RTL">تم الإبلاغ عن تفاعلات جلدية خطيرة لمرضى متلازمة ستيفنز جونسون وانحلال البشرة النخري السمي بالاقتران مع العلاج بالميسالازين. توقف عن استخدام الميسالازين واطلب العناية الطبية فورًا إذا لاحظت أيًا من الأعراض المرتبطة بتفاعلات الجلد الخطيرة الموضحة في القسم 4.</p><p dir="RTL">يجب الحذر عند إعطاء أساكول للمرضى الذين يعانون من ضعف في وظائف الكبد أو الكلى والمرضى الذين سبق أن حدثت لديهم تفاعلات فرط حساسية تؤثر على القلب (التهاب العضلة القلبية والتهاب التامور)، بغض النظر عن سببها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل وأثناء العلاج بأساكول سينظر طبيبك في مدى حاجتك إلى إجراء فحوصات منتظمة للتأكد من أن الكبد والكلى والرئتين والدم في حالة طبيعية. ننصحك بالالتزام بجميع مواعيد الاختبارات التي يحددها لك طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب بدء العلاج بحذر إذا كنت مصاباً بقرحة معدية أو معوية أو مرض رئوي، خاصة الربو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المرضى الذين يعانون من مشاكل وراثية نادرة مثل عدم تحمل الجلاكتوز أو عوز اللاكتاز أو سوء امتصاص الجلوكوز يجب عليهم استشارة الطبيب قبل بدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ورد عدد محدود من التقارير عن وجود أقراص كاملة من الدواء في البراز. ولكن هذه الأقراص التي تبدو كاملة هي على الأرجح الأغلفة الفارغة للأقراص.</p><p dir="RTL">إذا لاحظت وجود أقراص في برازك بصورة متكررة، فيجب عليك استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة المرضى المسنين، لا يُنصح باستخدام أساكول إلا إذا كانت وظائف الكلى والكبد طبيعية، ويجب توخي الحذر بشكل عام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتكون حصى الكلى مع استخدام ميسالازين. وقد تشمل الأعراض ألم في جانبي البطن ودم في البول. احرص على شرب كمية كافية من السوائل خلال علاجك بميسالازين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">لا يُنصح باستخدام أساكول للأطفال إلا في عمر 6 سنوات فأكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من تناول</strong><strong> </strong><strong>الأساكول</strong><strong> </strong><strong>مع أي أدوية أخرى أو أعشاب أو مكملات</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تعاني من أمراض أخرى أو حساسية أو إذا كنت تتناول أو تستخدم أدوية أخرى بصورة خارجية (بما في ذلك الأدوية التي تُباع دون وصفة طبية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المعروف أن أساكول يتفاعل مع وارفارين وفينبروكومون (مضادات التخثر) وأزاثيوبرين (وهو مثبط للمناعة) وميركابتوبورين وثيوجوانين (مثبطات الخلايا).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتسبب الميسالازين في تغير لون البول إلى اللون الأحمر البني بعد التلامس مع مبيض هيبوكلوريت الصوديوم في ماء المرحاض. يتعلق بتفاعل كيميائي بين الميسالازين والمبيض وهو غير ضار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل والرضاعة الطبيعية</p><p dir="RTL">يُفرز أساكول في حليب الأم. لذلك يجب عدم استخدامه أثناء الحمل والرضاعة الطبيعية إلا بعد استشارة الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">القيادة واستخدام الآلات</p><p dir="RTL">أساكول ليس له تأثير أو تأثير ضئيل على القدرة على القيادة واستخدام الآلات. ومع ذلك ، إذا تأثرت بأي شكل من الأشكال ، فلا تقم بالقيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعمل هذا الدواء دوماً حسب إرشادات طبيبك. وإذا كان لديك أي شك فاستشر طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تناول أساكول قبل وجبات الطعام. ويجب بلع الأقراص كاملة، ويستحسن أن يكون ذلك مع بعض السوائل. لا تمضغ الأقراص أو تسحقها أو تكسرها قبل بلعها.</p><p dir="RTL">أثناء تناول هذا الدواء، تأكد من شرب كميات كافية من السوائل للمحافظة على ترطيب الجسم، خاصة بعد حدوث نوبات شديدة أو طويلة من القيء أو الإسهال أو ارتفاع الحرارة أو التعرق الشديد، وذلك لتجنب حدوث مشاكل في الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها:</p><p dir="RTL"><strong>للبالغين (بما في ذلك كبار السن)</strong></p><p dir="RTL">الجرعة اليومية لعلاج التهاب القولون التقرحي هي من 6 إلى 12 قرصاً. إذا كانت الجرعة 6 أقراص في اليوم فيمكن تناولها معاً أو تقسيمها إلى جرعات (حسب نصيحة طبيبك). أما إذا كانت الجرعة أكثر من 6 أقراص يومياً فيجب تقسيمها إلى جرعات.</p><p dir="RTL">الجرعة اليومية لمنع التهاب كرونز اللفائفي والقولون أو التهاب القولون التقرحي هي من 3 إلى 6 أقراص يمكن تناولها معاً أو تقسيمها إلى جرعات. اتبع تعليمات طبيبك. لا تتناول أكثر من 12 قرصاً في اليوم، ولا تتناول أكثر من 6 أقراص معاً في الوقت ذاته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للأطفال والمراهقين</p><p dir="RTL">لا يُنصح باستخدام أساكول للأطفال إلا في عمر 6 سنوات فأكثر. وتعتمد الجرعة اليومية على وزن الطفل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج المراحل الحادة من التهاب القولون التقرحي:</p><p dir="RTL">إذا كان الوزن 20-30 كغ: من قرصين إلى 3 أقراص في اليوم.</p><p dir="RTL">إذا كان الوزن 30-40 كغ: من قرصين إلى 4 أقراص يومياً مع التقسيم إلى جرعات.</p><p dir="RTL">إذا كان الوزن أكثر من 40 كغ: من 3 إلى 5 أقراص يومياً مع التقسيم إلى جرعات.</p><p dir="RTL">يجب ألا تتجاوز الجرعة الإجمالية 4 غرامات في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمنع التهاب القولون التقرحي أو التهاب كرونز اللفائفي والقولون:</p><p dir="RTL">إذا كان الوزن 20-30 كغ: قرص واحد في اليوم.</p><p dir="RTL">إذا كان الوزن 30-40 كغ: من قرص إلى قرصين في اليوم.</p><p dir="RTL">إذا كان الوزن أكثر من 40 كغ: من قرص إلى 2 أقراص في اليوم مع التقسيم إلى جرعات.</p><p dir="RTL">يجب ألا تتجاوز الجرعة الإجمالية غرامين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوصى عموماً بإعطاء نصف جرعة البالغين للأطفال الذين يبلغ وزنهم 40 كغ فما دون، وجرعة البالغين العادية للأطفال الذين يزيد وزنهم عن 40 كغ.</p><p dir="RTL">لا تغيّر الجرعة التي وصفها لك الطبيب. إذا شعرت أن مفعول الدواء ضعيف جداً أو قوي جداً، فاستشر طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تجاوز الجرعة المحددة من أساكول</p><p dir="RTL">يجب ألا تتجاوز الجرعة الموصوفة لك. لا تأخذ جرعة أعلى مما وصفه طبيبك لك. اتصل بأقرب قسم للإسعاف أو بالطبيب للحصول على المشورة إذا تناولت أنت أو أي شخص آخر الكثير من الأقراص أو إذا كنت تعتقد أن طفلًا قد ابتلع أيًا منها. خذ هذه النشرة وأي أقراص متبقية معك كي يراها الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نسيان تناول أساكول</p><p dir="RTL">إذا نسيت أن تتناول أحد الأقراص، فقم بتناول أحدها بمجرد تذكرها، إلا إذا كان الوقت قد حان لتناول الجرعة التالية. لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التوقف عن تناول أساكول</p><p dir="RTL">لا تتوقف عن تناول أو استخدام أساكول دون التحدث إلى طبيبك أولاً حتى لو كنت تشعر بتحسن. إذا كانت لديك أي أسئلة أخرى حول استخدام هذا المنتج، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول أساكول مع الطعام والشراب</p><p dir="RTL">يجب تناول الأقراص قبل تناول الطعام مع كوب من السوائل إن أمكن ذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، قد يسبب هذا الدواء بعض الآثار الجانبية، ولكنها لا تصيب الجميع. لقد تم الإبلاغ عن آثار جانبية تصيب أعضاء مُحددة مثل القلب، والرئتين، والكبد، والكلى، والبنكرياس، والبشرة والنسيج تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>توقف عن تناول أساكول واطلب النصيحة الطبية الفورية إذا لاحظت أيًا من الأعراض التالية</u></strong><strong><u>:</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء غير مرتفعة ،&nbsp;شبيهة بلوح التصويب&nbsp;أو دائرية على منطقة الجذع ، غالبًا يُصاحبها بثور مركزية ، وتقشير الجلد ، وتقرحات في الفم ، والحلق ، والأنف ، والأعضاء التناسلية والعينين ، وطفح جلدي منتشر ، وحمى ، وتضخم في الغدد الليمفاوية. يمكن أن يُسبق هذا الطفح الجلدي الشديد بحمى وأعراض تشبه أعراض الأنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بكدمات لا تفسير لها (دون إصابة)، نزيف أسفل البشرة، نقاط أو بقع بنفسجية أسفل البشرة، فقر دم (الشعور بالتعب والضعف والشحوب، خاصة على الشفاه والأظافر وداخل الجفون)، حمّى (درجة حرارة مرتفعة)، التهاب الحلق أو نزيف غير طبيعي (مثل نزيف الأنف).</p><p>&nbsp;</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية بنسب التكرار التقريبية الموضحة:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; عسر هضم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; حمّى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; عدد مرتفع من خلايا الدم البيضاء تُسمى الخلايا الحبيبية الحمضية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إحساس بالوخز واللسع والخدران</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; قشعريرة، حكة البشرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التهاب القلب مع علامات مثل ألم في الصدر أو خفقان القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الإسهال، ألم المعدة، ريح (انتفاخ)، الشعور بالإزعاج وعدم الارتياح في المعدة مع رغبة في التقيوء، والتقيوء الفعلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تحسس زائد لبشرتك من الشمس والأشعة فوق البنفسجية (الحساسية الضوئية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النادرة جداً</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; انخفاض حاد في خلايا الدم قد يتسبب بالضعف أو التكدم أو قد يزيد من احتمالية الإصابة بالالتهابات، انخفاض عدد خلايا الدم؛ انخفاض في عدد الصفائح الدموية يزيد من خطر النزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية مثل الطفح الجلدي أو ثوران الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; حمّى تحدث أثناء تناول الدواء وتختفي عند إيقاف الدواء (حمى الدواء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مرض في الجهاز المناعي قد يصيب الأعضاء والمفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التهاب القولون التقرحي يشمل كامل الأمعاء الغليظة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اعتلال أو تضرر الأعصاب يؤدي إلى الشعور بالخدران أو الوخز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مرض الرئة (تندب أنسجة الرئة، رد فعل تحسسي) يؤدي إلى صعوبة في التنفس والسعال والصفير وإلى تجمع السوائل في الرئتين، الالتهاب الرئوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التهاب البنكرياس (يصاحبه ألم في الجزء العلوي من المعدة والظهر والشعور بالمرض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لفحوصات وظائف الكبد، التهاب الكبد الوبائي (التهاب للكبد يؤدي إلى ظهور أعراض شبيهة بأعراض الانفلونزا واليرقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في العضلات أو المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; فقدان الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مشاكل في الكلى (مثل التهاب الكلى وتندبها)، فشل كلوي، قد يكون قابل للعكس في حال إيقاف العلاج في وقت مُبكر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; انخفاض عكسي في إنتاج الحيوانات المنوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير المعروفة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اضطراب في الجهاز المناعي (متلازمة شبيهة بالذئبة) قد يتسبب بالتهاب كيس القلب أو الأغشية حول الرئتين والقلب، والطفح الجلدي و/أو ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التهاب أغشية التجويف الجنبي المحيط بالرئتين (التهاب الجنبة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; عدم تحمل للميسالازين يصاحبه أحياناً تفاقم أعراض المرض الكامن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; خروج نتائج الفحوصات المخبرية عن معدلاتها الطبيعية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; حصوات الكلى وما يصاحبها من آلام في الكلى (انظر أيضًا القسم 2).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تقييم الآثار الجانبية قائم على نسب التكرار التالية:</p><p dir="RTL">شائعة: قد تصيب لغاية شخص 1 من بين كل 10 أشخاص</p><p dir="RTL">غير شائعة: قد تصيب لغاية شخص 1 من بين كل 100 شخص</p><p dir="RTL">نادرة: قد تصيب لغاية شخص 1 من بين كل 1.000 شخص</p><p dir="RTL">نادرة جداً: قد تصيب لغاية شخص 1 من بين كل 10.000 شخص</p><p dir="RTL">غير معروفة: لا يمكن تقدير نسبة التكرار من البيانات المتوفرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تخزين أقراص أساكول المقاومة لحموضة المعدة في علبتها الأصلية بدرجة حرارة لا تتجاوز 25 درجة مئوية وفي مكان محمي من الرطوبة وأشعة الشمس المباشرة.</p><p dir="RTL">ينبغي عدم استخدام هذا الدواء بعد انتهاء تاريخ الصلاحية (&quot;EXP&quot;) المطبوع على العلبة. يُحفظ بعيداً عن مرأى الأطفال ومتناولهم.</p><p dir="RTL">يمكنك الحصول على المزيد من المعلومات من طبيبك أو من الصيدلي، فلديهما معلومات شاملة حول وصف الدواء.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المُبين على الجهة الخارجية من العلبة. لا تتخلص من أية أدوية من خلال مياه الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي حول كيفية التخلص من الأدوية التي لم تعد تستعملها. هذه الإجراءات ستساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي القرص الواحد من أساكول 400 ملغ المقاوم لحموضة المعدة على 400 ملغ من الميسالازين.</p><p dir="RTL">المكونات الأخرى هي: لاكتوز مونوهيدرات ، بوفيدون E1201 ، نشا الصوديوم جلايكولات ، التلك E 553 ب ، ستيرات المغنيسيوم ، ثلاثي إيثيل سيترات ، التلك E553b ، أكاسيد الحديد الأصفر والأحمر E172 ، حمض الميثاكريليك- ميثيل ميثاكريلات كوبوليمر 1: 2 ، ماكروغول 6000.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">في الصيدليات عند تقديم وصفة الطبيب.</p><p dir="RTL">تباع أقراص أساكول 400 ملغ المقاومة لحموضة المعدة في علب تحتوي كل واحدة منها على 50 قرصاً.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب تصريح التسويق هو:</strong></p><p dir="RTL">تيلوتس فارما إيه جي ، بازلرشتراسه 15 4310 راينفيلدن ، سويسرا</p><p>&nbsp;</p><p dir="RTL">الشركة المُصنّعة هي:</p><p dir="RTL">هاوبت فارما وولفينج جي إم بي إتش، دي- 31028 جروناو، ألمانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><br />&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>المملكة العربية السعودية:</em></strong></p><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='width:411.6pt;height:120pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.45pt'><span lang=AR-SA dir=RTL
    style='mso-ansi-font-size:11.5pt;mso-ansi-font-weight:bold;mso-ansi-font-style:
    italic'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-right:5.15pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA>المركز الوطني للتيقظ
    الدوائي</span><span dir=LTR></span><span dir=LTR><span dir=LTR></span>: </span><span
    lang=AR-SA><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-right:5.15pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-right:5.15pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA>مركز االتصال الموحد:
    19999<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-right:5.15pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-right:5.15pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA>البريد الإلكتروني </span><span
    dir=LTR>npc.drug@sfda.gov.sa :</span><span lang=AR-SA><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-right:5.15pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal dir=RTL style='margin-right:5.15pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA>الموقع الإلكتروني </span><span
    dir=LTR>https://ade.sfda.gov.sa :</span><span lang=AR-SA><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="555" height="166" alt="Text Box: المركز الوطني للتيقظ الدوائي: 

مركز االتصال الموحد: 19999

البريد الإلكتروني npc.drug@sfda.gov.sa :

الموقع الإلكتروني https://ade.sfda.gov.sa :
" src="file:///C:/Users/BASEL~1.SHB/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:411.6pt;
 height:120pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>دول الخليج العربي الأخرى:</em></strong></p><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='width:324.9pt;height:33pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText><b style='mso-bidi-font-weight:normal'><i
    style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;
    mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></i></b></p>
    <p class=MsoNormal dir=RTL style='margin-right:41.15pt;text-align:right;
    text-indent:-.25in;mso-list:l2 level1 lfo2;tab-stops:41.15pt 41.2pt;
    direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:11.5pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol;color:red'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>الرجاء الاتصال بالجهات الوطنية في كل دولة</span><span dir=LTR
    style='font-size:11.5pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="439" height="50" alt="Text Box: •	الرجاء الاتصال بالجهات الوطنية في كل دولة
" src="file:///C:/Users/BASEL~1.SHB/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:324.9pt;
 height:33pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">مجلس وزراء صحة العرب:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>إن هذا الدواء</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك واستهلاكه خلافا للتعليمات يعرضك للخطر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطبيب والصيدلي هما الخبيران في الدواء، وفي نفعه وضرره.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب المختص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تترك الأدوية في متناول الأطفال.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة نشرة معلومات المريض هذه في نوفمبر 2022.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Asacol 400 mg gastro-resistant tablets, 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each gastro-resistant tablet contains: 400 mg mesalazine.
Excipient with known effect: 76.4 mg lactose monohydrate see section 4.4.
For a full list of excipients see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gastro-resistant (GR) tablets.
Coated, red/brown oblong tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Asacol is indicated in adults, children and adolescents above 6 years for:</p><p><em>Ulcerative Colitis: </em></p><p>For the treatment of mild to moderate acute exacerbations. For the maintenance of remission.</p><p><em>Crohn&#39;s ileo-colitis: </em></p><p>For the maintenance of remission.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology </u></p><p><u>Adults </u></p><p>Mild acute disease: 2.4g (six tablets) once daily or in divided doses, with concomitant corticosteroid therapy to be taken when clinically indicated.</p><p>Moderate acute disease: 2.4g to 4.8g (six to twelve tablets) a day in divided doses, with concomitant corticosteroid therapy where clinically indicated. 2.4g may be taken once daily or in divided doses. Above 2.4g daily should be taken in divided doses.</p><p>Maintenance therapy: 1.2g to 2.4g (three to six tablets) taken once daily or in divided doses.</p><p>The maximum adult dose should not exceed twelve tablets a day and not exceed six tablets taken together at any one time.</p><p><u>Elderly population </u></p><p>The normal adult dosage may be taken unless liver or renal function is severely impaired (see sections 4.3 and 4.4). No studies have been carried out in the elderly population.</p><p><u>Paediatric population </u></p><p>There is only limited documentation for an effect in children (age 6-18 years).</p><p><u>Children 6 years of age and older </u></p><p>&bull; Active disease: To be determined individually, starting with 30-50 mg/kg/day in divided doses. Maximum dose: 75 mg/kg/day in divided doses. The total dose should not exceed 4 g/day.</p><p>&bull; Maintenance treatment: To be determined individually, starting with 15-30 mg/kg/day in divided doses. The total dose should not exceed 2 g/day.</p><p>It is generally recommended that half the adult dose may be given to children up to a body weight of 40 kg; and the normal adult dose to those above 40 kg.</p><p><u>Method of administration:</u> Oral.</p><p>The tablets must be swallowed whole preferably with some liquid before food intake. They must not be chewed, crushed or broken before swallowing. If one or more doses have been missed, the next dose is to be taken as usual.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to mesalazine or to any of the excipients listed in section 6.1.
-	Known allergy to salicylates.
-	Severe liver impairment.
-	Severe renal impairment (GFR < 30 mL/min/1.73m2).
-	Children under 2 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blood tests (differential blood count, liver function parameters such as ALT or AST; serum creatinine) and urinary status (dip sticks) should be determined prior to and during treatment, at the discretion of the treating physician. As a guideline, follow-up tests are recommended 14 days after commencement of treatment and then every 4 weeks for the following 12 weeks. If the findings are normal, follow-up tests should be carried out every three months. If additional signs appear, these tests should be performed immediately.</p><p><u>Renal impairment</u></p><p>Caution should be exercised in patients with raised blood urea or proteinuria. The possibility of mesalazine-induced nephrotoxicity must be considered in patients developing impairment of renal function during treatment. Treatment with Asacol should be stopped <u>immediately</u> if there is evidence of renal impairment and patients should seek immediate medical advice.</p><p><u>Nephrolithiasis</u></p><p>Cases of nephrolithiasis have been reported with the use of mesalazine including stones with a 100% mesalazine content. It is recommended to ensure adequate fluid intake during treatment.</p><p>Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach (e.g., in toilets cleaned with sodium hypochlorite contained in certain bleaches).</p><p><u>Severe cutaneous adverse reactions</u></p><p>Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment.</p><p>Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p><u>Blood dyscrasia</u></p><p>Serious blood dyscrasia has been reported. Asacol therapy should be stopped <u>immediately</u> if there is a suspicion or evidence of blood dyscrasia (signs of unexpected bleeding, haematoma, purpura, anaemia, persistent fever or sore throat) and patients should seek immediate medical advice.</p><p><u>Hepatic impairment</u></p><p>There have been reports of increased liver enzyme levels in patients taking preparations containing mesalazine. Caution is recommended if Asacol is administered to patients with liver impairment.</p><p><u>Cardiac hypersensitivity reactions</u></p><p>Mesalazine-induced cardiac hypersensitivity reactions (myo- and pericarditis) have been reported rarely with Asacol. In case of known previous mesalazine-induced cardiac hypersensitivity Asacol must not be administered. Caution should be taken in patients with previous myocarditis or pericarditis of allergic background regardless of its &nbsp;origin.</p><p><u>Pulmonary</u><u> disease</u></p><p>Patients with lung disease, especially asthma, should be monitored with particular care during treatment with Asacol.</p><p>&nbsp;</p><p><u>Adverse drug reactions</u><u> to Sulphasalazine</u></p><p>Patients with a history of adverse drug reactions to sulphasalazine therapy should be kept only under close medical supervision. Treatment must be stopped <u>immediately</u> if acute symptoms of intolerance occur such as abdominal cramps, acute abdominal pain, fever, severe headache and rash.</p><p><u>Gastric and duodenal</u><u> ulcers</u></p><p>In case of existing gastric or duodenal ulcers treatment should begin with caution based on theoretical grounds.</p><p><u>Intolerance to carbohydrates</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><u>Tablets in stool</u></p><p>A limited number of reports of intact tablets in the stool have been received. What appear to be intact tablets may in some cases represent largely empty shells of the coated tablets. If intact tablets are observed in the stool repeatedly, the patient should consult his/her physician.</p><p><u>Elderly population</u></p><p>Use in older people should be handled with caution and the product should only be prescribed to patients having a normal or non-severely impaired liver and renal function, see section 4.3.</p><p><u>Paediatric population</u></p><p>There is only limited documentation for an effect in children (age 6-18 years), see section 4.2</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>No interaction studies have been performed.</em></p><p>There is weak evidence that mesalazine might decrease the anticoagulant effect of warfarin.</p><p>In patients who are concomitantly treated with azathioprine, 6-mercaptopurine or thioguanine, a possible increase in the myelosuppressive effects of azathioprine, or 6-mercaptopurine or thioguanine should be taken into account. As a result, life-threatening infection can occur. Patients should be closely observed for signs of infection and myelosuppression. Haematological parameters, especially the leucocyte, thrombocyte, and lymphocyte cell counts should be monitored regularly (weekly), especially at initiation of such combination therapy, see section 4.4. If white blood cells are stable after 1 month, testing every 4 weeks for the following 12 weeks followed by 3 monthly monitoring intervals appears to be justified.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data from the use of Asacol in pregnant women. However, in a limited number of pregnant women exposed to mesalazine (627), no negative effects were found with regard to pregnancy or foetal/neonatal health. No other relevant epidemiological data are currently available.</p><p>&nbsp;In one single case, after long-term use of a high mesalazine dose (2 - 4 g, orally) during pregnancy, renal failure in a neonate was reported . Animal studies with oral mesalazine administration do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.</p><p>Asacol should only be used during pregnancy when the expected benefit outweighs the potential risk.</p><p><u>Breastfeeding </u></p><p>N-acetyl-5-aminosalicylic acid and to a lesser degree mesalazine are excreted in breast milk. The clinical significance of this has not been determined. Only limited experience during lactation in women is available to date. Hypersensitivity reactions such as infant diarrhoea cannot be excluded. Therefore, Asacol should only be used during breastfeeding when the expected benefit outweighs the potential risk. If the infant develops diarrhoea, breastfeeding should be discontinued.</p><p><u>Fertility</u></p><p>No effects on fertility have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Asacol has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Summary of safety profile</em></p><p>Organ specific adverse drug reactions affecting the heart, lungs, liver, kidneys, pancreas, skin and subcutaneous tissue have been reported.</p><p>Treatment must be stopped <u>immediately</u> if acute symptoms of intolerance occur, such as cramps, abdominal pain, fever, severe headache or rash.</p><p>Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see section 4.4).</p><p><em>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Tabulated summary of adverse reactions</em></p><p>The evaluation of side effects is based on the following frequencies:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &ge; 1/100 and &lt; 1/10,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: &ge; 1/1,000 and &lt; 1/100,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: &ge; 1/10,000 and &lt; 1/1,000,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare: &lt; 1/10,000,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not known (cannot be estimated from the available data)</p><p>Undesirable effects relevant for the labelling reported from eight (8) double-blind and five (5) open clinical studies with 739 patients treated with Asacol 400 mg GR tablets are listed below:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:907px"><thead><tr><td><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common </strong></p><p><strong>(&ge; 1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&nbsp;(&ge; 1/1,000 to &lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 to &lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p><strong>(&lt; 1/10,000)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eosinophilia (as part of an allergic reaction)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Altered blood count (aplastic anaemia, agranulocytosis, pancytopenia, neutropenia, leukopenia, thrombocytopenia)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions, such as allergic exanthema, drug fever, lupus erythematosus syndrome, pancolitis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paresthesia</p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocarditis, Pericarditis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic and fibrotic lung reactions (including dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis), interstitial pneumonia, eosinophilic pneumonia, lung disorder</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pleurisy</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Dyspepsia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain, diarrhoea, flatulence, vomiting, nausea</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Changes in liver function parameters (increase transaminases and cholestasis parameters), hepatitis, cholestatic hepatitis.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Urticaria, pruritus.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Photosensitivity*</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal, connective tissue and bone disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia; arthralgia,</p></td><td style="vertical-align:top"><p>Lupus-like syndrome with pericarditis and pleuropericarditis as prominent symptoms, as well as rash and arthralgia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Impairment of renal function&nbsp; including acute and chronic interstitial nephritis and renal insufficiency, nephrotic syndrome, renal failure, which can be reversible on early withdrawal</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nephrolithiasis**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oligospermia (reversible)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia, chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Intolerance to mesalazine with C-reactive protein increased and/or exacerbation of symptoms of underlying disease.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased, weight decreased, creatinine clearance decreased, amylase increased, red blood cell sedimentation rate increased, lipase increased, BUN increased</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>* see section c)</p><p>** see section 4.4 for further information</p></td></tr></tbody></table><p>&nbsp;</p><p><em>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Description of selected adverse reactions</em></p><p>An unknown number of the above undesirable effects are probably related to the underlying IBD rather than Asacol/mesalazine medication. This holds true especially for gastrointestinal undesirable effects, arthralgia, and alopecia.</p><p>To avoid a blood dyscrasia resulting from developing bone marrow depression, patients should be monitored with care, see section 4.4.</p><p>Under co-administration of mesalazine with immunosuppressive drugs, such as azathioprine, 6-MP or thioguanine, &nbsp;life threatening infection can occur, see section 4.5.</p><p><u>Photosensitivity</u></p><p>More severe reactions are reported in patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema.</p><p><em>d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Paediatric population</em></p><p>There is only limited safety experience with the use of Asacol tablets in the paediatric population. It is expected that the target organs of possible adverse reactions in the paediatric population are the same as for adults (heart, lungs, liver, kidneys, pancreas, skin and subcutaneous tissue.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the following route:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is little data on overdose (e.g., intended suicide with a high oral dose of mesalazine), which do not indicate any renal or hepatic toxicity. There is no known specific antidote and treatment is symptomatic and supportive.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Intestinal anti-inflammatory agents; ATC code: A07E C02.</p><p><u>Mechanism of action:</u></p><p>Asacol contains mesalazine, also known as 5-aminosalicylic acid, which has an anti-inflammatory effect through a mechanism that has not yet been fully clarified. Mesalazine has been shown to inhibit LTB4-stimulated migration of intestinal macrophages and thus may reduce intestinal inflammation by restricting migration of macrophages to inflamed areas. The production of pro-inflammatory leukotrienes (LTB4 and 5-HETE) in macrophages of the intestinal wall is inhibited. Mesalazine has been shown to activate PPAR-&gamma; receptors which counteract nuclear activation of intestinal inflammatory responses.</p><p><u>Pharmacodynamic effects</u></p><p>Under trial conditions mesalazine inhibited the cyclooxygenase and thus, the release of thromboxane B2 and prostaglandin E2, but the clinical meaning of this effect is still unclear. Mesalazine inhibits the formation of platelet activating factor (PAF). Mesalazine is also an antioxidant; it has been shown to decrease formation of reactive oxygen products and to capture free radicals.</p><p>There is a possibility that regular mesalazine use reduces the risk of colorectal cancer. Continued long-term mesalazine maintenance treatment may therefore reduce the risk of colon cancer.</p><p><u>Clinical efficacy and safety</u></p><p>Asacol 800 mg Tablets have been evaluated in 140 patients with mild to moderate active ulcerative colitis in one controlled study lasting for 10 weeks comparing safety and efficacy versus placebo.</p><p>This indication was also investigated in seven controlled and three open clinical trials including 787 patients, of whom 559 received Asacol 400 mg Modified Release Tablets. Three studies were placebo-controlled, one of which also compared the efficacy of Asacol to another proprietary oral mesalazine product. Five studies were performed without comparator. The studies included dose ranging of Asacol. One study compared the efficacy of mesalazine versus sulfasalazine. The studies included dose ranging of Asacol from 1.2 g/day to 4.8 g/day. One study used computerised morphometry to assess the efficacy of Asacol compared with a prednisolone enema. These studies established the safety and efficacy of Asacol for the treatment of mild to moderate acute UC at daily doses of 2.4 &ndash; 4.8 g mesalazine.</p><p><em>Maintenance of remission of ulcerative colitis </em></p><p>This indication was studied in five controlled and two open clinical trials involving 677 patients, of whom 406 received Asacol 400 mg Modified Release Tablets. Asacol treatment was compared to sulfasalazine in three studies, to another proprietary oral mesalazine product in one study, and to placebo in one study. The dosage varied from 0.8 - 4.4 g mesalazine per day. These studies established the safety and efficacy of Asacol for the maintenance of remission of UC at daily doses of 1.6 &ndash; 2.4 g mesalazine.</p><p><em>Maintenance of remission of Crohn&#39;s ileo-colitis </em></p><p>This indication was studied in one double blind, one retrospective and two open clinical studies involving 336 patients, of whom 159 received Asacol 400 mg Modified Release Tablets. Asacol treatment was compared to sulfasalazine in one study and to placebo or no specific treatment in three studies. Two studies confirmed efficacy in preventing post-operative recurrence of Crohn&#39;s disease. These studies support the safety and efficacy of Asacol in the treatment of quiescent Crohn&#39;s disease of the terminal ileum and colon including post-operative patients at a daily dose of 2.4 g mesalazine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong></p><p>Asacol tablets are coated with a pH responsive polymer which enables the release of mesalazine only at a pH above 7, i.e., within the terminal ileum and colon, which are the main sites of inflammation in IBD. After any initial disruption of the coating mesalazine will continue to be released irrespective of the pH. Asacol tablets have been designed to minimize absorption in the digestive tract.</p><p>After a single dose of 2.4 g of mesalazine (6 Asacol 400 mg GR Tablets) in healthy volunteers under fasting conditions quantifiable amounts (&gt; 2.00 ng/mL) of mesalazine were observed in plasma after 4.5 h (median t<sub>lag</sub>). The geometric mean C<sub>max</sub> &ndash;value of mesalazine was 722.11 ng/mL with a median t<sub>max</sub> of about 9.5 h, whereas that of N-acetyl mesalazine was 1437.90 ng/mL with a median t<sub>max</sub> of 12.0 h.</p><p>Based on the recovery of unchanged mesalazine and the main metabolite N-acetyl mesalazine in collected urine after fasted oral administration approximately 25% of the dose (more than 95 % as metabolite) was excreted renally within 60 h.</p><p>Following concomitant food intake in the same study a single dose of 2.4 g of mesalazine resulted in quantifiable amounts of mesalazine after 9.0 h (median tlag). The geometric mean C<sub>max</sub> &ndash;value of mesalazine was 1725.93 ng/mL with a median tmax of about 22.0 h, whereas that of N-acetyl mesalazine was 2235.32 ng/mL with a median t<sub>max</sub> of 24.0 h.</p><p>Based on the recovery of unchanged mesalazine and the main metabolite N-acetyl mesalazine in collected urine after fed oral administration approximately 30% of the dose (about 90 % as metabolite) was excreted renally within 60 h.</p><p>Following concomitant food intake, the C<sub>max</sub>-values of mesalazine increased 2.39-fold, and the extent of exposure (AUC0-tlast) increased 1.57-fold. Concerning N-acetyl mesalazine after concomitant food intake the C<sub>max</sub>-values increased 1.55-fold, whereas its extent of exposure increased about 1.1-fold only.</p><p><strong>Distribution:</strong></p><p>About 43% mesalazine and about 78% N-acetyl mesalazine are bound to plasma proteins. Approximately 75 % of the administered dose remains in the gut lumen and the mucosal tissue. The mean apparent volume of distribution per kg of body weight (Vd<sub>w</sub>) was 59.07 L/kg (geometric mean: 48.86 L/kg) after a single dose of 2.40 g of mesalazine (6 GR tablets of Asacol 400 mg) in healthy volunteers under fasting conditions. Based upon the absorption of 24.8% of the administered dose, this parameter is equal to 14.65 L/kg (geometric mean: 12.12 L/kg).</p><p>Low concentrations of mesalazine and N-acetyl mesalazine have been detected in human breast milk. The clinical significance of this has not been determined.</p><p><strong>Biotransformation:</strong></p><p>Mesalazine is metabolised both by the intestinal mucosa and the liver to the inactive metabolite N-acetyl mesalazine. At least 90% of the drug recovered in the urine after oral administration is found as the main metabolite N-acetyl-mesalazine.</p><p><strong>Elimination:</strong></p><p>The elimination of mesalazine is essentially urinary and faecal in the form of mesalazine and its N-acetyl metabolite. The geometric mean of total apparent clearance of mesalazine after administration of 2.40 g of mesalazine (6 GR tablets of Asacol 400 mg) in healthy volunteers under fasting conditions was about 135 L/h (geometric mean, CV% = 61.43%, intersubject). The median elimination half-life was 20 h ranging from 5 to 77 h. About 25% of the total dose administered was recovered in the urine within 60 h after fasted administration mainly as N-acetyl mesalazine and as the parent compound (about 1 %).</p><p><strong>Linearity/non-linearity:</strong></p><p>In a cross-over design with 3 test periods and 3 ascending oral doses of Asacol 400 mg GR Tablets administered 6 hourly over 4 consecutive doses (total daily dose of mesalazine: 3200, 4800, 6400 mg) it was shown that the absorption and elimination kinetics for mesalazine are dose independent for the 3 doses evaluated. For each dose, about &frac34; of the dose was available for the therapeutic activity for the colon. Only about &frac14; of each dose was absorbed and excreted in the urine, primarily as the metabolite. Based on urine drug excretion, plasma drug C<sub>max</sub>&#39;s and the combined plasma AUC&#39;s, there was a linear dose response for the 3 Asacol tablet doses. The clinical performance of Asacol 400 should be similar for the range of doses evaluated in this study.</p><p><strong>Pharmacokinetic/pharmacodynamics relationship(s)</strong></p><p>No specific studies have been performed.</p><p><strong>Kinetics in specific patient groups:</strong></p><p>Kinetics in specific patient groups (e.g., in hepatic and renal insufficiency, genetic polymorphisms) has not been investigated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No mutagenicity or clastogenic activity was found for mesalazine in the Ames Test and no carcinogenicity in animal trials. In a study on bone marrow in mice no micronucleus induction was demonstrated. In human lymphocytes no micronucleus induction or sister chromatid exchange was demonstrated for the primary metabolite N-acetyl-mesalazine. In studies on rats (360 mg/kg) or rabbits (480 mg/kg) no indications of an increased teratogenic risk were found. Mesalazine did not affect fertility in rats of either sex. The results of reproduction studies in female animal models did not indicate any negative effects on fertility, gestation, labour, parturition, lactation or viability.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate</p><p>Sodium starch glycolate (type A)</p><p>Magnesium stearate (vegetable origin) E 572</p><p>Talc E553b</p><p>Povidone</p><p>Methacrylic acid-methylmethacrylate copolymer (1:2)</p><p>Triethylcitrate</p><p>Ferric oxide yellow E172</p><p>Ferric oxide red E172</p><p>Macrogol 6000</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the reach of children. Do not store above 25&deg;C. Store in the original package to protect the content from moisture and direct sunlight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister strips of aluminium foil and PVC, and outer cardboard carton containing 50 tablets per pack. Each blister contains 10 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tillotts Pharma AG
Baslerstrasse 15
4310 Rheinfelden
Switzerland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>